Heron Therapeutics Inc (HRTX)
2.345
+0.02
(+1.08%)
USD |
NASDAQ |
May 01, 16:00
2.345
0.00 (0.00%)
After-Hours: 17:59
Heron Therapeutics Cash from Financing (TTM): 54.11M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 54.11M |
September 30, 2023 | 54.35M |
June 30, 2023 | 75.49M |
March 31, 2023 | 75.49M |
December 31, 2022 | 75.06M |
September 30, 2022 | 75.11M |
June 30, 2022 | 0.094M |
March 31, 2022 | 154.51M |
December 31, 2021 | 156.03M |
September 30, 2021 | 161.30M |
June 30, 2021 | 161.90M |
March 31, 2021 | 9.481M |
December 31, 2020 | 9.105M |
September 30, 2020 | 168.47M |
June 30, 2020 | 171.86M |
March 31, 2020 | 180.39M |
December 31, 2019 | 186.42M |
September 30, 2019 | 24.36M |
June 30, 2019 | 0.577M |
March 31, 2019 | 360.15M |
December 31, 2018 | 357.61M |
September 30, 2018 | 501.12M |
June 30, 2018 | 526.17M |
March 31, 2018 | 132.13M |
December 31, 2017 | 293.73M |
Date | Value |
---|---|
September 30, 2017 | 148.64M |
June 30, 2017 | 194.43M |
March 31, 2017 | 220.52M |
December 31, 2016 | 57.46M |
September 30, 2016 | 57.73M |
June 30, 2016 | 8.368M |
March 31, 2016 | 137.64M |
December 31, 2015 | 137.99M |
September 30, 2015 | 136.57M |
June 30, 2015 | 135.49M |
March 31, 2015 | 64.03M |
December 31, 2014 | 62.11M |
September 30, 2014 | 121.25M |
June 30, 2014 | 121.81M |
March 31, 2014 | 61.58M |
December 31, 2013 | 61.23M |
September 30, 2013 | 1.754M |
June 30, 2013 | 51.17M |
March 31, 2013 | 54.12M |
December 31, 2012 | 53.51M |
September 30, 2012 | 53.32M |
June 30, 2012 | 5.302M |
March 31, 2012 | 24.10M |
December 31, 2011 | |
September 30, 2011 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.094M
Minimum
Jun 2022
186.42M
Maximum
Dec 2019
94.43M
Average
75.49M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
United Therapeutics Corp | -11.90M |
Esperion Therapeutics Inc | 50.46M |
Aldeyra Therapeutics Inc | -1.270M |
Ocular Therapeutix Inc | 169.83M |
Clearside Biomedical Inc | 0.414M |